Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
PfizerPFE |
$13M |
 |
AstrazenecaAZN |
-$3.6M |
 |
Johnson & JohnsonJNJ |
-$566M |
 |
ModernaMRNA |
-$1.33B |
 |
AbbVieABBV |
-$360M |
Are TherapeuticsMD Insiders Buying or Selling?
TherapeuticsMD (TXMD) has had no reported insider transactions in the past 90 days. The most recent was Tommy Thompson, who bought 8,400 shares at $1.67 on December 23, 2025.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the TXMD AI Score. For government officials trading this stock, see TXMD congressional trading.
Who’s Trading TherapeuticsMD Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Tommy Thompson | Bought $14,000 | 2 | Dec 23, 2025 |
| Marlan Walker | Bought $2,500 | 3 | Apr 14, 2025 |
Recent TherapeuticsMD Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Tommy Thompson | Dec 23, 2025 | Buy | 8,400 | $1.67 | $14,000 |
| Tommy Thompson | Apr 14, 2025 | Buy | 325 | $1 | $330 |
| Marlan Walker | Apr 14, 2025 | Buy | 490 | $1 | $490 |
| Marlan Walker | Apr 10, 2025 | Buy | 1,167 | $0.86 | $1,000 |
| Marlan Walker | Apr 9, 2025 | Buy | 1,136 | $0.87 | $990 |
Frequently Asked Questions: TherapeuticsMD Insider Trading
TherapeuticsMD insiders have not reported any transactions in the past 90 days.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Thompson Tommy G has bought the most TXMD stock in the last 2 years, with a total value of $14,000.
According to our estimates, the total value of insider transactions for TherapeuticsMD in the last 2 years is positive, amounting to $17,000. This indicates that insiders have predominantly bought shares, showcasing their confidence in the company's future prospects.
